U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2017
411
Substance Class Protein
Created
by admin
on Mon Mar 31 20:36:15 GMT 2025
Edited
by admin
on Mon Mar 31 20:36:15 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG4
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
P93RUU11P7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INOTUZUMAB OZOGAMICIN
INN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
BESPONSA
Preferred Name English
WAY-207294
Code English
INOTUZUMAB OZOGAMICIN [MART.]
Common Name English
Inotuzumab ozogamicin [WHO-DD]
Common Name English
CMC-544
Code English
IMMUNOGLOBULIN G4 (ANTI-(HUMAN CD22 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL G544 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL G544 .KAPPA.-CHAIN, DIMER, METHYL ((1R,4Z,8S,13E)-8-((2-O-(4-(ACETYLETHYLAMINO)-2,4-DIDEOXY-3-O-METHYL-.ALPHA.-L-THREO-PENTOPY
Common Name English
INOTUZUMAB OZOGAMICIN [MI]
Common Name English
INOTUZUMAB OZOGAMICIN [JAN]
Common Name English
INOTUZUMAB OZOGAMICIN [USAN]
Common Name English
PF-05208773
Code English
inotuzumab ozogamicin [INN]
Common Name English
INOTUZUMAB OZOGAMICIN [PURPLE BOOK CDER]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/13/1127
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
NDF-RT N0000193617
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
NCI_THESAURUS C155713
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
WHO-ATC L01XC26
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
FDA ORPHAN DRUG 391413
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
Code System Code Type Description
DRUG CENTRAL
5247
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
INN
8574
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
DAILYMED
P93RUU11P7
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
MESH
C480122
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
MERCK INDEX
m12031
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
NCI_THESAURUS
C71542
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
USAN
QQ-54
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
RXCUI
1942950
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
WIKIPEDIA
INOTUZUMAB OZOGAMICIN
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
EVMPD
SUB33081
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
FDA UNII
P93RUU11P7
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
CAS
635715-01-4
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
LACTMED
Inotuzumab Ozogamicin
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108611
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
SMS_ID
100000125897
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
DRUG BANK
DB05889
Created by admin on Mon Mar 31 20:36:15 GMT 2025 , Edited by admin on Mon Mar 31 20:36:15 GMT 2025
PRIMARY
From To
1_20 1_94
2_20 2_94
2_133 4_219
2_146 2_202
2_260 2_320
1_133 3_219
2_366 2_424
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
1_146 1_202
1_225 2_225
1_228 2_228
1_260 1_320
1_366 1_424
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_296
N 2_296
Related Record Type Details
B-CELL RECEPTOR CD22
TARGET -> INHIBITOR
INOTUZUMAB
CONJUGATE COMPONENT->CONJUGATE
Structure of OZOGAMICIN
TOXIN -> CONJUGATE
Related Record Type Details
INOTUZUMAB
METABOLITE -> PARENT
Structure of N-ACETYL-.GAMMA.-CALICHEAMICIN DIMETHYLHYDRAZIDE
METABOLITE ACTIVE -> PARENT
Related Record Type Details
INOTUZUMAB OZOGAMICIN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_1] [2_1] N-TERMINUS PIDOLIC ACID SZB83O1W42
AMINO_ACID_SUBSTITUTION RESIDUE_SPECIFIC K Amount: OZOGAMICIN LYSINE 606387782B
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966